Privileged structures - dream or reality: preferential organization of azanaphthalene scaffold.

The concept of privileged structures/substructures (PS) is the idea that certain structural features produce biological effects more often than others. The PS method can be seen as an offspring of fragonomics, which is based on recent experimental measurements of protein-ligand interactions. If PS prove to be true, then chemical motives that enrich biological activity can be used when designing new drugs. However, PS remain controversial because we cannot be sure whether the excess of active structures does not result from an abundance in chemical libraries. In this review, we will focus, in particular, on the preferential organization of azanaphthalene scaffolds (AN) in drugs and natural products (NP), which are preferred by Nature in evolution. We will show that knowledge discovery in molecular databases can reveal interesting time-trends profiles for important classes of potentially privileged scaffolds. The chemical library of AN is dominated by monoaza-compounds, among which quinoline appears to be the most frequently investigated scaffold; however; more sophisticated database mining seems to indicate different PS patterns within the AN scaffold family.

[1]  Yuhua Chen,et al.  Vasodilatation produced by fasudil mesylate in vivo and in vitro. , 2011, Vascular pharmacology.

[2]  Tudor I. Oprea,et al.  Property distribution of drug-related chemical databases* , 2000, J. Comput. Aided Mol. Des..

[3]  Ichiro Katayama,et al.  Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases , 2009, Expert opinion on pharmacotherapy.

[4]  P. R. Vuddanda,et al.  Berberine: a potential phytochemical with multispectrum therapeutic activities , 2010, Expert opinion on investigational drugs.

[5]  D. MacMillan,et al.  Enantioselective organocatalytic indole alkylations. Design of a new and highly effective chiral amine for iminium catalysis. , 2002, Journal of the American Chemical Society.

[6]  Dan C. Fara,et al.  Lead-like, drug-like or “Pub-like”: how different are they? , 2007, J. Comput. Aided Mol. Des..

[7]  Jürgen Bajorath,et al.  Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.

[8]  B F King,et al.  In search of selective P2 receptor ligands: interaction of dihydropyridine derivatives at recombinant rat P2X(2) receptors. , 2000, Journal of the autonomic nervous system.

[9]  George Karypis,et al.  Common Pharmacophore Identification Using Frequent Clique Detection Algorithm , 2009, J. Chem. Inf. Model..

[10]  Samuel I Stupp,et al.  Antitumor activity of peptide amphiphile nanofiber-encapsulated camptothecin. , 2011, ACS nano.

[11]  Miklos Feher,et al.  Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry , 2003, J. Chem. Inf. Comput. Sci..

[12]  C. Kamei,et al.  Anticonvulsant Properties of 1,4-Benzodiazepine Derivatives in Amygdaloid-Kindled Seizures and Their Chemical Structure-Related Anticonvulsant Action , 1998, Pharmacology.

[13]  Stephan B Felix,et al.  Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application , 2009, Expert opinion on drug metabolism & toxicology.

[14]  Manuel Urbano-Cuadrado,et al.  Computational medicinal chemistry in fragment-based drug discovery: what, how and when. , 2011, Future medicinal chemistry.

[15]  M. Murcko,et al.  Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. , 2008, Journal of medicinal chemistry.

[16]  Jörg Rademann,et al.  Design of chemical libraries with potentially bioactive molecules applying a maximum common substructure concept , 2009, Molecular Diversity.

[17]  Jürgen Bajorath,et al.  Mining of Randomly Generated Molecular Fragment Populations Uncovers Activity-Specific Fragment Hierarchies , 2007, J. Chem. Inf. Model..

[18]  Eliezer J Barreiro,et al.  Privileged structures: a useful concept for the rational design of new lead drug candidates. , 2007, Mini reviews in medicinal chemistry.

[19]  M. Finn,et al.  2,6-Dichloro-9-thiabicyclo[3.3.1]nonane: a privileged, bivalent scaffold for the display of nucleophilic components. , 2001, The Journal of organic chemistry.

[20]  R G Smith,et al.  Synthesis and biological activities of phenyl piperazine-based peptidomimetic growth hormone secretagogues. , 1998, Bioorganic & medicinal chemistry letters.

[21]  Ronni Wolf,et al.  Quinine sulfate and HSV replication. , 2003, Dermatology online journal.

[22]  Tracy T Batchelor,et al.  Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. , 2011, Cancer research.

[23]  Eugen Lounkine,et al.  Random molecular fragment methods in computational medicinal chemistry. , 2008, Current medicinal chemistry.

[24]  Philip J. Hajduk,et al.  Fragment-based lead discovery: challenges and opportunities , 2011, J. Comput. Aided Mol. Des..

[25]  Joseph M. Blandeau Expanded activity and utility of the new fluoroquinolones: A review , 1999 .

[26]  Veerabahu Shanmugasundaram,et al.  Molecular similarity measures. , 2011, Methods in molecular biology.

[27]  François Nosten,et al.  The reality of using primaquine , 2010, Malaria Journal.

[28]  Gisbert Schneider,et al.  SVM-Based Feature Selection for Characterization of Focused Compound Collections , 2004, J. Chem. Inf. Model..

[29]  H Hunt Batjer,et al.  Endovascular treatment strategies for cerebral vasospasm. , 2006, Neurosurgical focus.

[30]  Brigitte Frey Tirri,et al.  Antimicrobial Topical Agents Used in the Vagina , 2011 .

[31]  T. O'Brien,et al.  Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.

[32]  Silvia Letasiová,et al.  Antiproliferative activity of berberine in vitro and in vivo. , 2005, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[33]  F. Vincenti,et al.  Sotrastaurin, a Novel Small Molecule Inhibiting Protein‐Kinase C: Randomized Phase II Study in Renal Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[34]  K. Chapman,et al.  Combinatorial synthesis of 3-(amidoalkyl) and 3-(aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G-protein coupled receptors. , 2002, Bioorganic & medicinal chemistry letters.

[35]  Qian Wang,et al.  In vivo and in vitro antiviral effects of berberine on influenza virus , 2011, Chinese journal of integrative medicine.

[36]  Elisabeth Heath,et al.  Cediranib inhibits both the intraosseous growth of PDGF D‐Positive prostate cancer cells and the associated bone reaction , 2012, The Prostate.

[37]  Oriana Tabarrini,et al.  6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors. , 2010, Future medicinal chemistry.

[38]  Michèle N Schulz,et al.  Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.

[39]  Iwao Ojima,et al.  Modern natural products chemistry and drug discovery. , 2008, Journal of medicinal chemistry.

[40]  W. Guida,et al.  The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.

[41]  G. Marshall,et al.  Privileged scaffolds targeting reverse-turn and helix recognition , 2008, Expert opinion on therapeutic targets.

[42]  J Polanski,et al.  Quinoline-based antifungals. , 2010, Current medicinal chemistry.

[43]  Gisbert Schneider,et al.  Scaffold diversity of natural products: inspiration for combinatorial library design. , 2008, Natural product reports.

[44]  Peter W Swaan,et al.  Camptothecins , 2012, Drugs.

[45]  Arthur M. Doweyko,et al.  QSAR: dead or alive? , 2008, J. Comput. Aided Mol. Des..

[46]  K C Nicolaou,et al.  Discovery of Novel Antibacterial Agents Active Against Methicillin‐Resistant Staphylococcus aureus from Combinatorial Benzopyran Libraries , 2001, Chembiochem : a European journal of chemical biology.

[47]  P. Hajduk,et al.  Privileged molecules for protein binding identified from NMR-based screening. , 2000, Journal of medicinal chemistry.

[48]  Yves Pommier,et al.  Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. , 2004, Current medicinal chemistry. Anti-cancer agents.

[49]  Matthew Clark,et al.  Generalized Fragment-Substructure Based Property Prediction Method , 2005, J. Chem. Inf. Model..

[50]  Alexander Tropsha,et al.  Recent Advances in Development, Validation, and Exploitation of QSAR Models , 2010, Burger's Medicinal Chemistry and Drug Discovery.

[51]  Clayton Springer,et al.  CoMFA and HQSAR of acylhydrazide cruzain inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[52]  Michal Vieth,et al.  Drugs in other drugs: a new look at drugs as fragments. , 2007, Drug discovery today.

[53]  G. Bemis,et al.  A minimalist approach to fragment‐based ligand design using common rings and linkers: Application to kinase inhibitors , 2004, Proteins.

[54]  R. Govindan,et al.  Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097) , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[55]  A. Caflisch,et al.  Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking. , 2006, Journal of medicinal chemistry.

[56]  R. Desimone,et al.  Privileged structures: applications in drug discovery. , 2004, Combinatorial chemistry & high throughput screening.

[57]  J. Larkin,et al.  A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours , 2011, British Journal of Cancer.

[58]  S Garattini,et al.  Are me-too drugs justified? , 1997, Journal of nephrology.

[59]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[60]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[61]  Christophe Cleva,et al.  Chemical substructures in drug discovery. , 2003, Drug discovery today.

[62]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[63]  Junmei Wang,et al.  GPCR Structure-Based Virtual Screening Approach for CB2 Antagonist Search , 2007, J. Chem. Inf. Model..

[64]  Gerhard Reichel,et al.  [Muscle cramps--differential diagnosis and therapy]. , 2009, Medizinische Monatsschrift fur Pharmazeuten.

[65]  Jeremy L. Jenkins,et al.  Clustering and Rule-Based Classifications of Chemical Structures Evaluated in the Biological Activity Space , 2007, J. Chem. Inf. Model..

[66]  Stefan Wetzel,et al.  Role of Natural Products in Drug Discovery , 2010 .

[67]  Yukihito Higashi,et al.  Rho-Associated Kinase Activity, Endothelial Function, and Cardiovascular Risk Factors , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[68]  Derek S. Tan,et al.  Diversity-oriented synthesis: exploring the intersections between chemistry and biology , 2005, Nature chemical biology.

[69]  Gregory Piatetsky-Shapiro,et al.  Knowledge Discovery in Databases: An Overview , 1992, AI Mag..

[70]  R. Shoemaker,et al.  β-Diketo Acid Pharmacophore Hypothesis. 1. Discovery of a Novel Class of HIV-1 Integrase Inhibitors , 2005 .

[71]  A. Schuffenhauer,et al.  Chemical diversity and biological activity , 2006 .

[72]  Imran Ahmad,et al.  Development and characterization of a novel liposome-based formulation of SN-38. , 2004, International journal of pharmaceutics.

[73]  Johan Vallon-Christersson,et al.  Open Access Research , 2022 .

[74]  Dvornik Dm Tissue selective inhibition of prostaglandin biosynthesis by etodolac. , 1997 .

[75]  Hugo Kubinyi,et al.  Chemical similarity and biological activities , 2002 .

[76]  Sophie Gale,et al.  28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics. , 2010, IDrugs : the investigational drugs journal.

[77]  Katrin Stierand,et al.  From Structure Diagrams to Visual Chemical Patterns , 2010, J. Chem. Inf. Model..

[78]  D. Harmon,et al.  Effect of ergot alkaloids on contractility of bovine right ruminal artery and vein. , 2011, Journal of animal science.

[79]  Iwao Kuwajima [Antihypertensive effects of nifedipine and changing for modified-release formula]. , 2006, Drugs.

[80]  D. Newell,et al.  Neurointerventional treatment of vasospasm , 2006, Neurological research.

[81]  Didier Rognan,et al.  Assessing the Scaffold Diversity of Screening Libraries , 2006, J. Chem. Inf. Model..

[82]  Gerhard Zenke,et al.  The Potent Protein Kinase C-Selective Inhibitor AEB071 (Sotrastaurin) Represents a New Class of Immunosuppressive Agents Affecting Early T-Cell Activation , 2009, Journal of Pharmacology and Experimental Therapeutics.

[83]  Jean-Francois Marier,et al.  Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors. , 2011, Journal of pharmaceutical sciences.

[84]  B. Grzybowski,et al.  The 'wired' universe of organic chemistry. , 2009, Nature chemistry.

[85]  W. Dinsmore,et al.  Available and future treatments for erectile dysfunction. , 2005, Clinical cornerstone.

[86]  Markus Wagener,et al.  Potential Drugs and Nondrugs: Prediction and Identification of Important Structural Features , 2000, J. Chem. Inf. Comput. Sci..

[87]  Isabelle Krimm,et al.  Ligand specificity, privileged substructures and protein druggability from fragment-based screening. , 2011, Current opinion in chemical biology.

[88]  Anatoly G. Artemenko,et al.  Virtual Screening and Molecular Design Based on Hierarchical Qsar Technology , 2009, Recent Advances in QSAR Studies.

[89]  P. LoRusso,et al.  Poly(ADP-Ribose) Polymerase Inhibitors: A Novel Drug Class With a Promising Future , 2010, Cancer journal.

[90]  A. Caflisch,et al.  Fragment-Based Flexible Ligand Docking by Evolutionary Optimization , 2001, Biological chemistry.

[91]  S. Eliasof,et al.  CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development , 2011, Current bioactive compounds.

[92]  Maria Laura Bolognesi,et al.  The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases , 2011, Expert opinion on drug discovery.

[93]  Christophe Biot,et al.  Ferroquine: a new weapon in the fight against malaria , 2004 .

[94]  Arvind Saklani,et al.  Plant-derived compounds in clinical trials. , 2008, Drug discovery today.

[95]  R. O'brien,et al.  Development of fluoroquinolones as first-line drugs for tuberculosis--at long last! , 2003, American journal of respiratory and critical care medicine.

[96]  J Rosenthal,et al.  Nilvadipine: profile of a new calcium antagonist. An overview. , 1994, Journal of cardiovascular pharmacology.

[97]  E. Barreiro,et al.  From nature to drug discovery: the indole scaffold as a 'privileged structure'. , 2009, Mini reviews in medicinal chemistry.

[98]  John J. M. Wiener,et al.  Scaffold explorer: an interactive tool for organizing and mining structure-activity data spanning multiple chemotypes. , 2010, Journal of medicinal chemistry.

[99]  Jong-Bae Kim,et al.  In vitro antibacterial activity of echinomycin and a novel analogue, YK2000, against vancomycin-resistant enterococci. , 2004, International journal of antimicrobial agents.

[100]  V. Solomon,et al.  Quinoline as a privileged scaffold in cancer drug discovery. , 2011, Current medicinal chemistry.

[101]  A. Dowson,et al.  Review of zolmitriptan and its clinical applications in migraine , 2002, Expert opinion on pharmacotherapy.

[102]  Ian A. Watson,et al.  Chemical fragments as foundations for understanding target space and activity prediction. , 2008, Journal of medicinal chemistry.

[103]  Gisbert Schneider,et al.  Properties and Architecture of Drugs and Natural Products Revisited , 2007 .

[104]  Ian M. Scott,et al.  Extracts of Canadian First Nations Medicinal Plants, Used as Natural Products, Inhibit Neisseria gonorrhoeae Isolates With Different Antibiotic Resistance Profiles , 2011, Sexually transmitted diseases.

[105]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[106]  Hong Zhao,et al.  Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. , 2008, Bioconjugate chemistry.

[107]  Jaroslaw Polanski,et al.  Mapping fragmental drug-likeness in the MoStBioDat environment: intramolecular hydrogen bonding motifs in β-ketoenols. , 2011, Combinatorial chemistry & high throughput screening.

[108]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[109]  A. Tutt,et al.  PARP inhibitors--current status and the walk towards early breast cancer. , 2011, Breast.

[110]  Solomon Habtemariam,et al.  The Therapeutic Potential of Berberis darwinii Stem-Bark: Quantification of Berberine and In Vitro Evidence for Alzheimer's Disease Therapy , 2011, Natural product communications.

[111]  A. B. Benson,et al.  A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma , 2008, Cancer Chemotherapy and Pharmacology.

[112]  Helen J. Mitchell,et al.  Natural Product-like Combinatorial Libraries Based on Privileged Structures. 1. General Principles and Solid-Phase Synthesis of Benzopyrans , 2000 .

[113]  Uwe Fuhr,et al.  Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors , 2011, Clinical pharmacokinetics.

[114]  A. Emmerson,et al.  The quinolones: decades of development and use. , 2003, The Journal of antimicrobial chemotherapy.

[115]  Valerie J. Gillet,et al.  SPROUT, HIPPO and CAESA: Tools for de novo structure generation and estimation of synthetic accessibility , 1995 .

[116]  J. Block,et al.  Raynaud's phenomenon , 2001, The Lancet.

[117]  Alexander Hillisch,et al.  In Silico ADMET Traffic Lights as a Tool for the Prioritization of HTS Hits , 2006, ChemMedChem.

[118]  Raimund Mannhold,et al.  Calculation of Drug Lipophilicity: The Hydrophobic Fragmental Constant Approach , 1992 .

[119]  P. Beroza,et al.  Target-related affinity profiling: Telik's lead discovery technology. , 2005, Current topics in medicinal chemistry.

[120]  Peter Neuhaus,et al.  Sotrastaurin single‐dose pharmacokinetics in de novo liver transplant recipients , 2011, Transplant international : official journal of the European Society for Organ Transplantation.

[121]  Seung Joon Baek,et al.  Berberine, a natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells. , 2007, Cancer letters.

[122]  D. J. Russell,et al.  Structure-activity studies of echinomycin antibiotics against drug-resistant and biofilm-forming Staphylococcus aureus and Enterococcus faecalis. , 2009, Bioorganic & medicinal chemistry letters.

[123]  Douglas A. Horton,et al.  The combinatorial synthesis of bicyclic privileged structures or privileged substructures. , 2003, Chemical reviews.

[124]  Edward R Zartler,et al.  Fragonomics: fragment-based drug discovery. , 2005, Current opinion in chemical biology.

[125]  Joseph Varon,et al.  A systematic review of nicardipine vs labetalol for the management of hypertensive crises. , 2012, The American journal of emergency medicine.

[126]  M. Prakash Hande,et al.  Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability , 1999, Nature Genetics.

[127]  Chia-Chi Lin,et al.  Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. , 2010, Discovery medicine.

[128]  Yoshihiro Fukumoto,et al.  Recent progress in the management of pulmonary hypertension. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[129]  G. Schneider,et al.  Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. , 2001, Journal of combinatorial chemistry.

[130]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[131]  Mario Jiménez-Hernández,et al.  Treatment of Raynaud's phenomenon. , 2008, Autoimmunity reviews.

[132]  J. Bajorath,et al.  Systematic analysis of public domain compound potency data identifies selective molecular scaffolds across druggable target families. , 2010, Journal of medicinal chemistry.

[133]  Jaroslaw Polanski,et al.  Receptor dependent multidimensional QSAR for modeling drug--receptor interactions. , 2009, Current medicinal chemistry.

[134]  J Jaworska,et al.  How can structural similarity analysis help in category formation? , 2007, SAR and QSAR in environmental research.

[135]  Andreas Bender,et al.  Molecular Similarity Searching Using Atom Environments, Information-Based Feature Selection, and a Naïve Bayesian Classifier , 2004, J. Chem. Inf. Model..

[136]  Tudor I. Oprea,et al.  Model-Free Drug-Likeness from Fragments , 2010, J. Chem. Inf. Model..

[137]  Federico Corelli,et al.  The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry. , 2009, Current medicinal chemistry.

[138]  Mayank Goel,et al.  Intravenous Diazepam, Midazolam and Lorazepam in Acute Seizure Control , 2012, The Indian Journal of Pediatrics.

[139]  Jaroslaw Polanski,et al.  Neural Nets for the Simulation of Molecular Recognition within MS-Windows Environment , 1996, J. Chem. Inf. Comput. Sci..

[140]  D. Fattori,et al.  Molecular recognition: the fragment approach in lead generation. , 2004, Drug discovery today.

[141]  A. Ganesan The impact of natural products upon modern drug discovery. , 2008, Current opinion in chemical biology.

[142]  N. Taira,et al.  [Nifedipine: a novel vasodilator]. , 2006, Drugs.

[143]  Zena Wilson,et al.  Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family , 2011, Molecular Cancer Therapeutics.

[144]  Thirunavukkarasu Arun Babu,et al.  Buclizine is back again! This time as a pediatric appetite stimulant , 2011, Indian journal of pharmacology.

[145]  H Denys,et al.  PARP INHIBITORS IN ONCOLOGY: A NEW SYNTHETIC LETHAL APPROACH TO CANCER THERAPY , 2011, Acta clinica Belgica.

[146]  F. Zunino,et al.  Current status and perspectives in the development of camptothecins. , 2002, Current pharmaceutical design.

[147]  Matthew E Welsch,et al.  Privileged scaffolds for library design and drug discovery. , 2010, Current opinion in chemical biology.

[148]  Marvin Johnson,et al.  Concepts and applications of molecular similarity , 1990 .

[149]  Jürgen Bajorath,et al.  Assessment of Molecular Similarity from the Analysis of Randomly Generated Structural Fragment Populations , 2006, J. Chem. Inf. Model..

[150]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[151]  Raffaele Izzo,et al.  Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia , 2010, Journal of hypertension.

[152]  Patricia Kraft,et al.  Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin’s lymphoma , 2009, Haematologica.

[153]  Wolfgang Guba,et al.  Development of a virtual screening method for identification of "frequent hitters" in compound libraries. , 2002, Journal of medicinal chemistry.

[154]  Andrew Good,et al.  Approaches to target class combinatorial library design. , 2004, Methods in molecular biology.

[155]  S. Khan,et al.  A brief history of malaria chemotherapy. , 2010, The journal of the Royal College of Physicians of Edinburgh.

[156]  Fumihiko Kajiya,et al.  Cardioprotective effect of hydroxyfasudil as a specific Rho-kinase inhibitor, on ischemia-reperfusion injury in canine coronary microvessels in vivo. , 2006, Clinical hemorheology and microcirculation.

[157]  Ian A. Watson,et al.  Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.

[158]  G. Bemis,et al.  Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.

[159]  Hiroshi Matsuda,et al.  Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease. , 2008, Clinical nuclear medicine.

[160]  Thomas Bäck,et al.  Mining a Chemical Database for Fragment Co-occurrence: Discovery of "Chemical Clichés" , 2006, J. Chem. Inf. Model..

[161]  Arup K. Ghose,et al.  Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. , 2008, Journal of medicinal chemistry.

[162]  Peter Ertl,et al.  Cheminformatics analysis of natural products: lessons from nature inspiring the design of new drugs. , 2008, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[163]  Paul Labute,et al.  Detection and assignment of common scaffolds in project databases of lead molecules. , 2009, Journal of medicinal chemistry.

[164]  Andrea Cipriani,et al.  Hydroxyzine for generalised anxiety disorder. , 2010, The Cochrane database of systematic reviews.

[165]  Gradman Ah The evolving role of calcium channel blockers in the treatment of angina pectoris: focus on felodipine. , 1995 .

[166]  Jhon J. Rojas,et al.  Screening for antimicrobial activity of ten medicinal plants used in Colombian folkloric medicine: A possible alternative in the treatment of non-nosocomial infections , 2006, BMC complementary and alternative medicine.

[167]  A. Dhir,et al.  Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders , 2010, Phytotherapy research : PTR.

[168]  A. Escobedo,et al.  Hospitalization of Cuban children for giardiasis: a retrospective study in a paediatric hospital in Havana , 2011, Annals of tropical medicine and parasitology.

[169]  Uwe Dr Petersen,et al.  Quinolone Antibiotics: The Development of Moxifloxacin , 2006 .

[170]  G. Klopman,et al.  Computer automated structure evaluation (CASE) of flavonoids as larval growth inhibitors , 1988 .

[171]  R. Owens,et al.  Antimicrobial safety: focus on fluoroquinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[172]  Xuechu Zhen,et al.  Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. , 2008, Bioorganic & medicinal chemistry.

[173]  Teodoro S. Kaufman,et al.  Die Jagd auf Chinin: Etappenerfolge und Gesamtsiege , 2005 .

[174]  A. Escobedo,et al.  Mebendazole in parasitic infections other than those caused by soil-transmitted helminths. , 2009, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[175]  Ajay,et al.  Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.

[176]  Kimito Funatsu,et al.  Novel Canonical Coding Method for Representation of Three-Dimensional Structures , 2000, J. Chem. Inf. Comput. Sci..

[177]  N. Agarwal,et al.  Novel molecular targets for the therapy of castration-resistant prostate cancer. , 2012, European urology.

[178]  R Wise,et al.  Norfloxacin--a review of pharmacology and tissue penetration. , 1984, The Journal of antimicrobial chemotherapy.

[179]  W. Couldwell,et al.  Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage , 2005, Neurocritical care.

[180]  P. Schultz,et al.  Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. , 1999, Chemistry & biology.

[181]  C. Dobson Chemical space and biology , 2004, Nature.

[182]  Christina Plaisier,et al.  Berberine acutely activates the glucose transport activity of GLUT1. , 2011, Biochimie.

[183]  Adriaan P. IJzerman,et al.  Computational Approaches to Fragment and Substructure Discovery and Evaluation , 2008 .

[184]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[185]  A. Michiel van Rhee,et al.  Use of Recursion Forests in the Sequential Screening Process: Consensus Selection by Multiple Recursion Trees , 2003, J. Chem. Inf. Comput. Sci..

[186]  Tao Jiang,et al.  A maximum common substructure-based algorithm for searching and predicting drug-like compounds , 2008, ISMB.

[187]  Dora M Schnur,et al.  Are target-family-privileged substructures truly privileged? , 2006, Journal of medicinal chemistry.

[188]  M. Jacobson,et al.  Binding-Site Assessment by Virtual Fragment Screening , 2010, PloS one.

[189]  Yun Yen,et al.  Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[190]  R. Glen,et al.  Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.

[191]  J. Ring,et al.  Demonstration of quinolone phototoxicity in vitro. , 1990, Dermatologica.

[192]  Junling Han,et al.  Modulating gut microbiota as an anti-diabetic mechanism of berberine , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[193]  G Klopman,et al.  Quantitative structure-activity relationships of beta-adrenergic agents. Application of the computer automated structure evaluation (CASE) technique of molecular fragment recognition. , 1986, Journal of theoretical biology.

[194]  Tudor I. Oprea,et al.  Pursuing the leadlikeness concept in pharmaceutical research. , 2004, Current opinion in chemical biology.

[195]  Patricia Kraft,et al.  Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model , 2008, Clinical Cancer Research.

[196]  J. Robinson,et al.  Evaluation of French Guiana traditional antimalarial remedies. , 2005, Journal of ethnopharmacology.

[197]  Tait Shanafelt,et al.  Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia , 2010, Leukemia & lymphoma.

[198]  Y. You,et al.  Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. , 2005, Journal of medicinal food.

[199]  Robert P. Sheridan,et al.  Chemical Similarity Using Physiochemical Property Descriptors , 1996, J. Chem. Inf. Comput. Sci..

[200]  Daniel J. Freeman,et al.  Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives. , 2011, Journal of medicinal chemistry.

[201]  G. Poirier,et al.  Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. , 1999, The Biochemical journal.

[202]  P. McDermott,et al.  Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. , 2006, Veterinary journal.

[203]  Karl Swedberg,et al.  Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals , 2011, Journal of hypertension.

[204]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[205]  H. Katz,et al.  Quinine-Induced Hypoglycemia , 1993, Annals of Internal Medicine.

[206]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[207]  W. Foulkes,et al.  BRCA1 and BRCA2: 1994 and beyond , 2004, Nature Reviews Cancer.

[208]  Jianjun Cheng,et al.  Antitumor Activity of β-Cyclodextrin Polymer−Camptothecin Conjugates , 2004 .

[209]  Claus Bachert,et al.  Efficacy of Second-Generation Antihistamines in Patients with Allergic Rhinitis and Comorbid Asthma , 2011, The Journal of asthma : official journal of the Association for the Care of Asthma.

[210]  Joseph C. Lin Rule of Three: a case of discrimination against certain authors caused by the cataloging rules , 1985 .

[211]  H Matter,et al.  Computational approaches towards the rational design of drug-like compound libraries. , 2001, Combinatorial chemistry & high throughput screening.

[212]  H. Kubinyi,et al.  A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.

[213]  Haruki Nakamura,et al.  Definition of Drug-Likeness for Compound Affinity , 2011, J. Chem. Inf. Model..

[214]  Frederick P. Roth,et al.  Chemical substructures that enrich for biological activity , 2008, Bioinform..

[215]  Satoru Todo,et al.  Sotrastaurin, a new selective protein kinase C inhibitor, on the way. , 2012, Transplantation.

[216]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[217]  Yuebo Zhang,et al.  Berberine inhibits PTP1B activity and mimics insulin action. , 2010, Biochemical and biophysical research communications.

[218]  Robert P Bywater,et al.  Recognition of privileged structures by G-protein coupled receptors. , 2004, Journal of medicinal chemistry.

[219]  M. Bolon,et al.  Newer fluoroquinolones , 2009, Infectious disease clinics of North America.

[220]  R. Venkataraghavan,et al.  Atom pairs as molecular features in structure-activity studies: definition and applications , 1985, J. Chem. Inf. Comput. Sci..

[221]  Carol A Barnes,et al.  Peripheral delivery of a ROCK inhibitor improves learning and working memory. , 2009, Behavioral neuroscience.

[222]  Kazunori Takada,et al.  Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction. , 2011, Bioorganic & medicinal chemistry.

[223]  Robert C. Glen,et al.  Novel Methods for the Prediction of logP, pKa, and logD , 2002, J. Chem. Inf. Comput. Sci..

[224]  S. Meshnick,et al.  Is chloroquine making a comeback? , 2011, The Journal of infectious diseases.

[225]  Padhraic Smyth,et al.  From Data Mining to Knowledge Discovery in Databases , 1996, AI Mag..

[226]  F H Allen,et al.  Intramolecular hydrogen bonds: common motifs, probabilities of formation and implications for supramolecular organization. , 2000, Acta crystallographica. Section B, Structural science.

[227]  John Heritage,et al.  Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms. , 2006, The Journal of antimicrobial chemotherapy.

[228]  Masahiro Fukuoka,et al.  Gefitinib in non-small cell lung cancer , 2005, Expert opinion on pharmacotherapy.

[229]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.

[230]  G. J. M. Parker,et al.  A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics , 2011, Cancer Chemotherapy and Pharmacology.

[231]  D. Ettlinger,et al.  Metabolic activation of irinotecan during intra-arterial chemotherapy of metastatic colorectal cancer. , 2011, Anticancer research.

[232]  Gisbert Schneider,et al.  Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.

[233]  J. Damber,et al.  Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer , 2009, British Journal of Cancer.

[234]  Yoshihiro Fukumoto,et al.  Rho-kinase: important new therapeutic target in cardiovascular diseases. , 2011, American journal of physiology. Heart and circulatory physiology.

[235]  Jaroslaw Polanski,et al.  The Receptor-like Neural Network for Modeling Corticosteroid and Testosterone Binding Globulins , 1997, J. Chem. Inf. Comput. Sci..

[236]  K. Hatzimouratidis,et al.  A Comparative Review of the Options for Treatment of Erectile Dysfunction , 2012, Drugs.

[237]  Daniel J. Graham,et al.  Information Content in Organic Molecules: Quantification and Statistical Structure via Brownian Processing , 2004, J. Chem. Inf. Model..

[238]  M. Fiałkowski,et al.  Architecture and evolution of organic chemistry. , 2005, Angewandte Chemie.

[239]  Roberto Todeschini,et al.  Molecular descriptors for chemoinformatics , 2009 .

[240]  Nouri Neamati,et al.  HIV-1 IN strand transfer chelating inhibitors: a focus on metal binding. , 2011, Molecular pharmaceutics.

[241]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[242]  Ju-Yeon Lee,et al.  Combinatorial Library Synthesis and Biological Evaluation of Pyrazolo[4,3‐e][1,4]diazepine as a Potential Privileged Structure , 2009, ChemMedChem.

[243]  Mary Anne Jackson,et al.  The Use of Systemic and Topical Fluoroquinolones , 2011, Pediatrics.

[244]  Vic Velanovich,et al.  Esomeprazole: a proton pump inhibitor , 2009, Expert review of gastroenterology & hepatology.

[245]  C. Ogilvy,et al.  Endovascular treatment of cerebral vasospasm: transluminal balloon angioplasty, intra-arterial papaverine, and intra-arterial nicardipine. , 2005, Neurosurgery clinics of North America.

[246]  Hye-Sook Kim,et al.  Synthesis and Biological Activity of Fatty Acid Derivatives of Quinine , 2005, Bioscience, biotechnology, and biochemistry.

[247]  Y. Pommier Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.

[248]  A. Shields,et al.  Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study , 2011, Investigational New Drugs.

[249]  G. Klopman Artificial intelligence approach to structure-activity studies. Computer automated structure evaluation of biological activity of organic molecules , 1985 .

[250]  M. Ranson,et al.  Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours , 2012, British Journal of Cancer.

[251]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[252]  David J Triggle,et al.  The chemist as astronaut: searching for biologically useful space in the chemical universe. , 2009, Biochemical pharmacology.

[253]  R. Ronimus,et al.  The composition of Ehrlich's salvarsan: resolution of a century-old debate. , 2005, Angewandte Chemie.

[254]  A. Ghose,et al.  Knowledge-based chemoinformatic approaches to drug discovery. , 2006, Drug discovery today.

[255]  Ola Engkvist,et al.  Molecular Topology Analysis of the Differences between Drugs, Clinical Candidate Compounds, and Bioactive Molecules , 2010, J. Chem. Inf. Model..

[256]  Jürgen Bajorath,et al.  Chemical Database Mining through Entropy-Based Molecular Similarity Assessment of Randomly Generated Structural Fragment Populations , 2007, J. Chem. Inf. Model..

[257]  Daniela Barlocco,et al.  Privileged Structures as Leads in Medicinal Chemistry , 2006 .

[258]  Luca Sartori,et al.  Identification and Selection of "Privileged Fragments" Suitable for Primary Screening , 2008, J. Chem. Inf. Model..

[259]  Maksimov Ml,et al.  [Application of AT1-angiotensin II receptor blocker valsartan in clinical practice]. , 2011 .

[260]  Lorenz C. Blum,et al.  Chemical space as a source for new drugs , 2010 .

[261]  Jiří Špaček,et al.  A Comparison of Dequalinium Chloride Vaginal Tablets (Fluomizin®) and Clindamycin Vaginal Cream in the Treatment of Bacterial Vaginosis: A Single-Blind, Randomized Clinical Trial of Efficacy and Safety , 2011, Gynecologic and Obstetric Investigation.

[262]  Lin Wu,et al.  Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. , 2008, Heart rhythm.

[263]  Eugen Lounkine,et al.  Mapping of Activity-Specific Fragment Pathways Isolated from Random Fragment Populations Reveals the Formation of Coherent Molecular Cores , 2007, J. Chem. Inf. Model..

[264]  Thomas Becker,et al.  The Novel Immunosuppressive Protein Kinase C Inhibitor Sotrastaurin Has No Pro-Viral Effects on the Replication Cycle of Hepatitis B or C Virus , 2011, PloS one.

[265]  Harren Jhoti,et al.  Pyramid: An Integrated Platform for Fragment‐based Drug Discovery , 2006 .

[266]  Hugo Kubinyi,et al.  Privileged Structures and Analogue‐Based Drug Discovery , 2006 .

[267]  Tudor I. Oprea Current trends in lead discovery: Are we looking for the appropriate properties? , 2002, J. Comput. Aided Mol. Des..

[268]  Chris L. Waller,et al.  A Comparative QSAR Study Using CoMFA, HQSAR, and FRED/SKEYS Paradigms for Estrogen Receptor Binding Affinities of Structurally Diverse Compounds , 2004, J. Chem. Inf. Model..